A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

Exclusion Criteria

• •Patients who cannot perform endoscopy
• •Finding of malignancy, duodenal ulcer, ulcer perforation, postoperative (eg, endoscopic mucosal resection, endoscopic submucosal dissection) ulcer(s), Barrett's oesophagus measuring \>3cm, oesophageal dysplasia, oesophageal and/or gastric varices, bleeding disorder on upper GI endoscopy
• •History of definitive acid lowering surgery or pervious oesophageal or gastric surgery (except for benign tumor excisionn, simple close of perforations)
• •Zollinger-Ellison syndrome, pyloric stenosis, oesophageal motility disorder, esophageal stricture
• •Severe hepatic disease
• •Severe renal disease, CKD
• •Bleeding disorder
• •History of malignancy or was treated for malignancy within 5 years before the start of the Visit 1
• •Patients who have taken drugs containing following list within 2 weeks prior to upper GI endoscopy, or requirement of persistent use of drugs during the study period: acid suppressive drugs, antacids, anticholinergic drugs, gastroprotective agent
• •Patients who have taken drugs containing following list within 1 weeks prior to upper GI endoscopy, or requirement of persistent use of drugs during the study period: antithrombotic agents, NSAIDs, aspirin
• •Requirement of use of excluded medications during the study
• •History of allergic reaction to the medications used in this study
• •Glucose-galactose malabsorption, Fructose intolerance, Sucrase-isomaltase deficiency
• •Use of other investigational drugs within 30 days prior to the study
• •History of alcohol or drug abuse
• •Positive to pregnancy test, nursing mother, intention on pregnancy
• •Considered by investigator as not appropriate to participate in the clinical study with other reason